DRTS · Small Cap · NASDAQ · Healthcare · Biotechnology
Free research brief
Free to track. No card required.
Price, momentum, and the numbers behind the story.
Overall score
53/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Lowest
$8
Current price
$14.61
Median target
$16
Highest
$17
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
Debt / equity
Favorable · 0.34 - strong leverage
0.34x
Current ratio
Strong · Good liquidity position
11.09x
ROIC
Weak · Weak capital efficiency
-39.6%
ROE
Needs attention · Unfavorable
-141.7%
DRTS against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $1.36B | - | - | 53 | |
| $10.51B | 20.0 | +19.7% | 78 | |
| $33.17B | 34.7 | +15.5% | 78 | |
| $4.12B | 12.4 | +13.5% | 78 | |
| $1.08T | 39.1 | +49.6% | 77 |